CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...